- Conditions
- Crohn Disease
- Interventions
- Tirzepatide, Mediterranean diet
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
- Conditions
- Weight Loss
- Interventions
- VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 110 more
- Conditions
- Overweight or Obesity
- Interventions
- Olatorepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Winter Park, Florida • San Antonio, Texas
- Conditions
- Post-Bariatric Hypoglycemia
- Interventions
- Dietary Intervention, GLP-1 receptor agonist or Dual GIP/GLP-1 receptor agonist, Transoral Outlet Reduction (TORe)
- Behavioral · Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Insulin Lispro (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
- Conditions
- Chronic Weight Management
- Interventions
- ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Overweight and Obesity
- Interventions
- Apitegromab, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Weight Loss
- Interventions
- VK2735, Placebo
- Biological
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
- Interventions
- Tirzepatide, Loperamide, Diphenoxylate/Atropine
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
- Conditions
- Endometrial Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Weight Loss
- Interventions
- Placebo, VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
- Conditions
- COPD, Obesity & Overweight, Sarcopenia
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Weight Loss
- Interventions
- VK2735
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more